Latest Regulatory Reforms News

Tempest Minerals has agreed to acquire a 145km² advanced gold portfolio in New Zealand’s North Island, unlocking multiple drill-ready targets in a prolific gold province. The $2 million all-scrip deal includes performance milestones tied to exploration success.

Little Green Pharma Ltd (ASX: LGP) has proposed a full acquisition of Cannatrek Ltd via a scheme of arrangement, creating a vertically integrated medicinal cannabis group with pro forma FY26 revenues exceeding AUD 100 million. The scheme, supported by an independent expert, offers liquidity and strategic growth opportunities amid regulatory and market risks.

The Star Entertainment Group reports a $110 million statutory loss for H1 FY26 as it undertakes major operational restructuring and seeks refinancing amid challenging market conditions.

The Star Entertainment Group reported a 10% drop in H1 FY26 revenue, offset by a 71% improvement in EBITDA, while navigating ongoing licence suspensions and a critical refinancing process.

Australian Unity Limited reported increased revenue for the half-year ending December 2025, but earnings declined sharply due to inflationary pressures and ongoing transformation investments. The company also completed a leadership transition and strengthened its balance sheet.

Mercury NZ Limited reported a 130% surge in net profit for HY2026, driven by strong renewable generation and disciplined cost management, while advancing major geothermal and wind projects on schedule.

Chorus Limited has reported a strong half-year performance driven by fibre broadband growth, operational efficiencies, and a return to profitability, while launching initiatives to boost digital inclusion.

Challenger Limited reported a solid first half of FY26 with a 2% rise in normalised net profit after tax and record annuity sales. The company also announced a $150 million on-market share buy-back, reflecting confidence in its strong capital position.

WT Financial Group Limited has reported a robust 16.1% increase in net revenue for the half-year ending December 2025, underpinned by strategic acquisitions and a pioneering joint venture. The company’s proprietary AI technology and industry consolidation efforts position it well for continued expansion.

Ryman Healthcare has unveiled a refreshed strategy focused on growing recurring earnings and optimising its portfolio, targeting a $150 million sustainable cash flow improvement and $500 million cash release by FY29. The company plans to resume dividends from FY28, underpinned by a resilient balance sheet and disciplined capital management.

Avecho Biotechnology is on the cusp of completing patient dosing in its pivotal Phase III CBD insomnia trial, backed by a recent $2.5 million capital raise and patent allowances in the US and Europe.

Bioxyne Limited has reported a record $17.2 million in quarterly revenue, driven by strong growth in its cannabis and psychedelics segments, alongside strategic international expansions including a Frankfurt dual listing and new manufacturing agreements.